Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP

Cell Biochemistry and Function

Volumn 33, Issue 5, 2015, Pages 326-333

  Lei, Chang Jiang ^a   Li, Lei ^a   Gao, Xia ^a   Zhang, Jun ^a   Pan, Qing Yun ^b   Long, Hao Cheng ^a   Chen, Chun Zhou ^a   Ren, De Fa ^a   Zheng, Gang ^a  

^a Fifth Hospital of Wuhan   (China)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Hepatic carcinoma cells; Hsa miR 132; MicroRNA; YAP

Indexed keywords

5 ETHYNYL 2' DEOXYURIDINE; ISOTHIOCYANIC ACID; LIPOCORTIN 5; MICRORNA 132; MICRORNA 200A; PROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; MICRORNA; MIRN132 MICRORNA, HUMAN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL GROWTH; CELL INVASION; CELL LEVEL; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; STAINING; TUMOR INVASION; VALIDATION STUDY; WESTERN BLOTTING; BIOLOGY; CHEMISTRY; LIVER TUMOR; METABOLISM; PATHOLOGY; PREVENTION AND CONTROL; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; HUMANS; LIVER NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS;

EID: 84937818309     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3119     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005; 19: 91-99.
3. Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006; 103: 12405-12410.
4. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120-1133.
5. Camargo FD, Gokhale S, Johnnidis JB, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007; 17: 2054-2060.
6. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-2761.
7. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 2005; 122: 421-434.
8. Zhou D, Conrad C, Xia F, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009; 16: 425-438.
9. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010; 24: 862-874.
10. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125: 1253-1267.
11. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115: 4576-4585.
12. Lee KP, Lee JH, Kim TS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A 2010; 107: 8248-8253.
13. Liu AM, Xu MZ, Chen J, Poon RT, Luk JM. Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets 2010; 14: 855-868.
14. Kowalik MA, Saliba C, Pibiri M, et al. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology 2011; 53: 2086-2096.
15. Perra A, Kowalik MA, Ghiso E, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol 2014; 61: 1088-1096.
16. Li H, Wolfe A, Septer S, et al. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int 2012; 32: 38-47.
17. Corvalan AH. Early diagnosis of hepatocellular carcinoma by microRNAs: shining a light from the genome's "dark matter". Dig Dis Sci 2012; 57: 2737-2739.
18. Huang YH, Lin KH, Chen HC, et al. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One 2012; 7: e37188.
19. Li SJ, Li XJ, Hou JF, et al. Hsa-miR-132 affects proliferation and invasion of esophageal carcinoma cells by targeting FOXA1 gene. Chin J Cancer Biother 2011; 18: 485-489.
20. Li XL, Chen T, Wong YS, et al. Involvement of mitochondrial dysfunction in human islet amyloid polypeptide-induced apoptosis in INS-1E pancreatic beta cells: an effect attenuated by phycocyanin. Int J Biochem Cell Biol 2011; 43: 525-534.
21. Chen T, Wong YS. In vitro antioxidant and antiproliferative activities of selenium-containing phycocyanin from selenium-enriched Spirulina platensis. J Agric Food Chem 2008; 56: 4352-4358.
22. Chen T, Wong YS. Selenocystine induces caspase-independent apoptosis in MCF-7 human breast carcinoma cells with involvement of p53 phosphorylation and reactive oxygen species generation. Int J Biochem Cell Biol 2009; 41: 666-676.
23. Liu W, Li X, Wong YS, et al. Selenium nanoparticles as a carrier of 5-fluorouracil to achieve anticancer synergism. ACS Nano. 2012; 28; 6: 6578-6591.
24. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 2010; 394: 623-627.
25. Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 2012; 23: 785-793.
26. Lu L, Li Y, Kim SM, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A 2010; 107: 1437-1442.
27. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13: 246-257.
28. Zhang T, Zhang J, You X, et al. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology 2012; 56: 2051-2059.
29. Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011; 104: 235-240.
30. Han ZB, Zhong L, Teng MJ, et al. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 2012; 6: 445-457.
31. Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19: 232-243.
32. Zhang S, Hao J, Xie F, et al. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis 2011; 32: 1183-1189.
33. Wei X, Tan C, Tang C, et al. Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. Cell Signal 2013; 25: 1037-1043.
34. Yu SJ, Hu JY, Kuang XY, et al. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res 2013; 19: 1389-1399.